1. |
胥少汀, 葛寶豐, 徐印坎. 實用骨科學. 北京: 人民軍醫出版社, 2005: 1539-1585.
|
2. |
Nielsen OS, Judson I, Van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas: a multicentre phaseⅡstudy of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2000, 36(1): 61-67.
|
3. |
Robinson MH. The management of adult soft tissue sarcomas. Clin Oncol, 1994, 6(3): 183-189.
|
4. |
Vraa S, Keller J, Nielsen OS, et al. Prognostic factors in soft tissue sarcomas: the Aarhus experience. Eur JCancer, 1998, 34(12): 1876-1882.
|
5. |
O’byrne K, Steward WP. The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. CritRev Oncol Hematol, 1998, 27(3): 221-227.
|
6. |
Verweij J, Mouridsen HT, Nielessen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit RevOncol Hematol, 1995, 20(3): 193-201.
|
7. |
Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlledsoft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol, 1996, 14(3): 869-877.
|
8. |
Alvegd TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol, 1989, 7(10): 1504-1513.
|
9. |
Edmonson JH, Fleming TR, Ivins JC, et al. Randomized study of systemic chemotherapy following complete excision of nonoesseous sarcomas. J Clin Oncol, 1984, 2(12): 1390-1396.
|
10. |
Chang AE, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol, 1988, 6(9): 1491-1500.
|
11. |
Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 1994, 12(6): 1137-1149.
|
12. |
Lerner HJ, Amato DA, Savlov ED, et al. Eastern Cooperative Oncology Group: A comparison of adjuvant doxorubicin and observation for patients with localized soft-tissue sarcoma. J Clin Oncol, 1987, 5(4): 613-617.
|
13. |
Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol, 2001, 19(5): 1238-1247.
|
14. |
Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol, 1997, 24: 556-560.
|
15. |
Benjamin RS. Evidence for using adjuvant chemotherapy as standard treatment of soft tissue sarcoma. Semin Radiat Oncol, 1999, 9(4): 349-351.
|
16. |
Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy associated outcomes. J Clin Oncol, 2004, 22(22): 4567-4574.
|
17. |
Bramwell VHC. Controversies in Surgical Oncology: Routine anthracyclinebased adjuvant chemotherapy for stage III extremity soft tissue sarcoma. Ann Surg Oncol, 2007, 14: 1254-1256.
|
18. |
Verweij J, Sejnaeve C. The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol, 1999, 9: 352-359.
|
19. |
Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology, 2003, 65(Suppl 2): 80-84.
|
20. |
Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol, 2004, 15(11): 1667-1672.
|